Trial Profile
A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Varoglutamstat (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms VIVA-MIND
- Sponsors Vivoryon Therapeutics
- 23 Oct 2023 According to a Vivoryon Therapeutics media release, the company is now recruiting participants into the second cohort with 21 sites open across the U.S.
- 23 Oct 2023 According to a Vivoryon Therapeutics media release, the study's independent data safety monitoring board (DSMB) unanimously recommend that the VIVA-MIND study of varoglutamstat should proceed with a dose of 600mg twice daily (BID) through the remainder of Phases 2a and 2b.
- 07 Sep 2023 According to a Vivoryon Therapeutics media release, in July 2023, company announced that the first cohort was fully randomized into the study.